16 October 2014
EMA/669514/2014

Annex I – Action plan

Actions	Estimated timeframes for completion
• Maintain the network of European patients' and consumers' organisations	On-going
• Establish a pool of experts: ⇒ Continue to identify through patients' and consumers' organisations, suitable independent experts who can make timely contributions to EMA scientific committees, working parties, scientific advisory groups, etc. ⇒ Identify gaps in expertise ⇒ On the basis of the gap analysis, publish a call for expression of interests from patients and members of the public willing to be involved in EMA activities	Q1 2016
• Promote participation at key milestones during the lifecycle of medicines: ⇒ Ensure early involvement in development of medicines/research focusing on patients values and preferences ⇒ Based on the outcome of the pilot phase of patients involvement in benefit/risk evaluation at CHMP, develop a process to capture patients' input on the value of evidence during benefit/risk evaluation	Q3 2016
• Build capacity: ⇒ Explore means to increase awareness on medicines evaluation in Europe ⇒ Organise a survey on the EMA provision of training to patients and consumers involved in its activities ⇒ Prepare an action plan on the basis of the outcome of the survey ⇒ Streamline provision of training by exploring synergies with other training initiatives within the Agency and at European level ⇒ Explore the use of social media ⇒ Conduct a reflection on providing further support to enable patients involvement in EMA activities	Q4 2016

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5550
Send a question via our website www.ema.europa.eu/contact

Actions	Estimated timeframes for completion
• Monitor and increase transparency on the involvement of patients, consumers and their organisations in the Agency's activities: ⇒ Establish a system for regular cross-Agency collection of quantitative and qualitative data for monitoring and reporting purposes ⇒ Explore methodologies to measure the impact of patients' involvement on regulatory outcomes ⇒ Acknowledge and promote visibility of patients' and consumers' organisations input provided in the context of the activities of scientific committees, working parties, scientific advisory groups and other expert groups	Q4 2016